>
Switch to:

Biomarin Pharmaceutical Capital Expenditure

: $-114.73 Mil (TTM As of Sep. 2021)
View and export this data going back to 1999. Start your Free Trial

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Biomarin Pharmaceutical's cash flow for capital expenditures for the three months ended in Sep. 2021 was $-20 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Sep. 2021 was $-114.73 Mil.

Biomarin Pharmaceutical Capital Expenditure Historical Data

The historical data trend for Biomarin Pharmaceutical's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Capital Expenditure
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -148.38 -199.22 -144.62 -163.41 -137.52

Biomarin Pharmaceutical Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Capital Expenditure Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.15 -39.86 -28.25 -26.25 -20.36

Biomarin Pharmaceutical Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Sep. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-114.73 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biomarin Pharmaceutical Business Description

Biomarin Pharmaceutical logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Comparable Companies
NAS:ALNY NAS:INCY NAS:ALXN NAS:SRPT NAS:NBIX NAS:BNTX NAS:TECH NAS:MRNA NAS:SGEN NAS:ACAD OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 XKRX:068270 HKSE:02269 OCSE:GMAB HKSE:01177 SZSE:300122
Traded in Other Exchanges
BMRN:Mexico 0HNC:UK BM8:Germany B1MR34:Brazil BMRN:Austria
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
Website
http://www.bmrn.com
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). BioMarin's Roctavian (hemophilia A gene therapy) and vosoritide (treatment for achondroplasia) are poised to potentially launch in the 2021-22 timeframe.
Executives
Ajer Jeffrey Robert officer: EVP, Chief Commercial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Heron Elaine J director 6 STONEGATE RD PONTOLA VALLEY CA 94028
Pyott David E I director C/O ALLERGAN 2525 DUPONT DRIVE IRVINE CA 92612
Grey Michael G director C/O SGX PHARMACEUTICALS, INC. 10505 ROSELLE STREET SAN DIEGO CA 92121
Fuchs Henry J officer: President, Worldwide R&D C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949
Acosta Andrea officer: GVP, Chief Accouning Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST SAN RAFAEL CA 94901
Dere Willard H director ONE AMGEN CENTER DRIVE THOUSAND OAKS CA 91320-1799
Lawlis V Bryan director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: LAWLIS V BRYAN a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Anderson Elizabeth M director 10 FINDERNE AVENUE BUILDING 10 BRIDGEWATER NJ 08807
Hombach Robert J. director C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Slamon Dennis director 770 LINDARO STREET SAN RAFAEL CA 94901
Meier Richard A director 1700 E ST ANDREW PLACE SANTA ANA CA 92705
Bienaime Jean Jacques director, officer: Chief Executive Officer 925 PAGE MILL ROAD PALO ALTO CA 94304
Guyer Charles Greg officer: EVP, Chief Technical Officer C/O BIOMARIN PHARMACEUTICAL INC. 770 LINDARO ST. SAN RAFAEL CA 94901
Mueller Brian officer: EVP, Chief Financial Officer C/O BIOMARIN PHARMACEUTICAL INC. 105 DIGITAL DRIVE NOVATO CA 94949

Biomarin Pharmaceutical Headlines

From GuruFocus

BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close

By PRNewswire 06-25-2021

Biomarin Pharmaceutical Stock Is Estimated To Be Modestly Undervalued

By GF Value 03-29-2021

Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $585,060 of Shares

By insider 02-23-2021

Biomarin Pharmaceutical Inc (BMRN) CEO Jean Jacques Bienaime Sold $595,560 of Shares

By insider 02-20-2021

BioMarin Announces Oral Presentation at International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress with 5 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec in Adults with Severe Hemophilia A, Demonstra

By PRNewswire 07-21-2021

Biomarin Pharmaceutical Inc (BMRN) EVP, CFO Brian Mueller Sold $533,366 of Shares

By insider 05-12-2021

BioMarin Announces 6 Presentations at American Society of Gene and Cell Therapy (ASGCT) Virtual 2021 Annual Meeting

By PRNewswire 05-12-2021

Allen Institute and BioMarin Team Up To Develop Gene Therapies For Rare Brain Diseases

By PRNewswire 04-28-2021

BioMarin to Participate in Four Upcoming Virtual Investor Conferences

By PRNewswire 02-24-2021

BioMarin to Host Second Quarter 2021 Financial Results Conference Call and Webcast on Wednesday, July 28 at 4:30pm ET

By PRNewswire 07-14-2021

Other Sources

BioMarin (BMRN) Upgraded to Strong Buy: Here's What You Should Know

By Zacks 2021-07-28

Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY

By Zacks 2021-07-27

Repligen (RGEN) Beats on Q2 Earnings & Sales, Ups 2021 View

By Zacks 2021-07-28

$BMRN - BioMarin: Depressed Price Due To CRL, Major Catalysts Ahead. Biomarin Depressed Price Due To Crl Major Catalysts Ahead

By Seekingalpha 2021-05-31

BioMarin's (BMRN) Vosoritide Gets CHMP Nod to Treat Dwarfism

By Zacks 2021-06-28

Albireo (ALBO) Gets FDA Nod for Rare Liver Disease Drug

By Zacks 2021-07-21

Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for

By Zacks 2021-04-22

$BMRN - BioMarin Pharmaceutical's (BMRN) CEO J.J. Bienaime on Q4 2020 Results - Earnings Call Transcript.…

By Seekingalpha 2021-02-26

BioMarin (BMRN) Re-Files MAA for Hemophilia Gene Therapy in EU

By Zacks 2021-06-29

BioMarin (BMRN) Gets EMA Validation for Hemophilia Gene Therapy

By Zacks 2021-07-16

BioMarin (BMRN) Down 7.7% Since Last Earnings Report: Can It Rebound?

By Zacks 2021-03-27

Arvinas (ARVN), Pfizer Team up for Breast Cancer Therapy

By Zacks 2021-07-23

Biotech Stock Roundup: REGN's Cocktail Approval, Updates From BMY, BMRN & VRTX

By Zacks 2021-07-21

Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline

By Zacks 2021-02-18

Vertex (VRTX) Initiates Phase II Study on Pain Candidate

By Zacks 2021-07-20

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)